Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2020-07-01
Serie:	Endocrinology, Diabetes & Metabolism
Soggetti:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
Accesso online:	https://doi.org/10.1002/edm2.159
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!